All In Biotech

Drug Trial Radar · NCT07421011

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

A Randomized, Open-label, Crossover Study to Assess the Comparative Pharmacokinetics, Bioequivalence, and Safety of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 6, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Valenta Pharm JSCIndustry
Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in healthy volunteers under fasted conditions.

Conditions

  • Irritable Bowel Syndrome
  • Gallstone Disease
  • GERD
  • Biliary Dyskinesia
  • Postcholecystectomy Syndrome

Interventions

  • Trimedat®Drug

    A single dose of R or T drug in each of 2 periods of the study under fasted conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics - CmaxTime frame: From 0 to 48 hours after each drug intake.
  2. Pharmacokinetics - tmaxTime frame: From 0 to 48 hours after each drug intake.
  3. Pharmacokinetics - AUC0-tTime frame: From 0 to 48 hours after each drug intake.
  4. Pharmacokinetics - AUC0-infTime frame: From 0 to 48 hours after each drug intake.
  5. Pharmacokinetics - AUCextrTime frame: From 0 to 48 hours after each drug intake.
  6. Pharmacokinetics - t1/2Time frame: From 0 to 48 hours after each drug intake.
  7. Pharmacokinetics - kelTime frame: From 0 to 48 hours after each drug intake.
  8. Pharmacokinetics - MRTTime frame: From 0 to 48 hours after each drug intake.
  9. Pharmacokinetics - VdTime frame: From 0 to 48 hours after each drug intake.
  10. Pharmacokinetics - CLTime frame: From 0 to 48 hours after each drug intake.
  11. Pharmacokinetics - number of terminal timepointsTime frame: From 0 to 24 hours after each drug intake.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Federal Budgetary Institution of Science "North-West Public Health Research Center"

    Saint Petersburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.